Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts
Anthony B. Rodriguez, J. David Peske, Amber N. Woods, Katie M. Leick, Ileana S. Mauldin, Max O. Meneveau, Samuel Young, Robin S. Lindsay, Marit M. Melssen, Salwador Cyranowski, Geoffrey Parriott, Mark R. Conaway, Yang‐Xin Fu, Craig L. Slingluff, Víctor H. Engelhard
Abstract
. Some of these elements are also overrepresented in human TA-TLS. Additionally, we demonstrate that immunotherapy induces more and larger TA-TLS that are more often organized with discrete T and B cell zones, and that TA-TLS presence, number, and size are correlated with reduced tumor size and overall response to checkpoint immunotherapy. This work provides a platform for manipulating TA-TLS development as a cancer immunotherapy strategy.
Topics & Concepts
Cancer immunotherapyLymphotoxinImmunotherapyCancer researchCD8Lymphotoxin beta receptorImmune systemCXCL13MelanomaBiologyCancer cellCancerTumor microenvironmentImmunologyChemokineGeneticsChemokine receptorCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionT-cell and B-cell Immunology